Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Lived Experience and Perceptions of Menopause Among Patients Participating in the Multidisciplinary Care Pathways at Paris Saint-Joseph Hospital

NCT07447947 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-05
Last updated
2026-03-04

Condition(s) studied

Menopause

Investigational drug(s) / intervention(s)

Focus Group

Focus Group: Women will participate in a focus group to discuss their Experiences and Perceptions of Menopause

Study summary

Menopause, often reduced to its biological aspects, is increasingly studied through medical, psychological, social, and cultural lenses. Women's experiences vary widely depending on context-country, era, and social status. Their perceptions are ambivalent: while some associate menopause with the end of fertility and burdensome physical symptoms (hot flashes, joint pain, sleep disorders, mood swings, brain fog, vaginal dryness, low libido, weight gain), others see it as a liberating phase, free from reproductive expectations. Surprisingly, 87% of women report a positive experience of menopause itself, though the transitional phase is less well-tolerated (78%).

In France, where women's life expectancy is 87, they spend a third of their lives post-menopause. Yet, menopause remains a taboo subject. While 87% of women aged 50-65 experience at least one symptom beyond the cessation of menstruation, 25% suffer severe symptoms. The silence around menopause is striking: 48% of women under 50 find it difficult to discuss, 39% of pre-menopausal women feel anxious, 46% have never discussed it with their partner, and only 61% have consulted a healthcare professional. This silence stems from outdated sexist views, societal valorization of youth, lack of intergenerational dialogue, and insufficient targeted health policies, leading to isolation and invisibility.

Medical support often focuses on a biomedical model, particularly Hormone Replacement Therapy (HRT), which remains controversial since the 2002 WHI study. Only 2.5% of French women over 45 currently use HRT, and 45.4% view it negatively. However, women's experiences extend far beyond hormonal concerns.

To address these gaps, multidisciplinary programs-such as those at Paris Saint-Joseph Hospital and Toulouse University Hospital-offer group-based approaches, addressing physical, psychological, and relational dimensions. These programs provide a much-needed space for exchange, often absent in traditional care. Research on the benefits of collective discussion spaces (in-person or digital) in menopause care is limited, making it relevant to explore how these programs influence women's perceptions of menopause, their bodies, and their healthcare journey. While qualitative studies have examined individual experiences, few have focused on the dynamics of shared dialogue.

Eligibility

Sex
FEMALE
Min age
45 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Women * Between age 45 and age 60 * French speaking * participating in the multidisciplinary program offered a the Paris Saint Joseph Hospital * Patient who does not object to the use of these data for research purposes Exclusion Criteria: * Patient under guardianship or conservatorship * Patient deprived of liberty (incarcerated or institutionalized) * Patient under judicial protection

Primary outcome measure(s)

  • Identify women's specific Experience and Perceptions of Menopause — 1 day

Trial sites (1)

FacilityCityRegionStatus
Hôpital Paris Saint Joseph Paris France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07447947 on ClinicalTrials.gov ↗ ← All trials in France